Actively Recruiting

Phase 2
Age: 18Years - 80Years
FEMALE
NCT06562166

Online Adaptive Radiotherapy for Cervical Cancer

Led by Peking Union Medical College Hospital · Updated on 2026-01-08

124

Participants Needed

1

Research Sites

221 weeks

Total Duration

On this page

Sponsors

P

Peking Union Medical College Hospital

Lead Sponsor

A

Affiliated Hospital of Jiangsu University

Collaborating Sponsor

AI-Summary

What this Trial Is About

This study aims to evaluate the clinical efficacy and safety of online adaptive radiotherapy for cervical cancer patients received radical radiotherapy. By comparing with image-guided radiotherapy, the study explores the potential advantages of online adaptive radiotherapy in reducing treatment toxicity and improving local control.

CONDITIONS

Official Title

Online Adaptive Radiotherapy for Cervical Cancer

Who Can Participate

Age: 18Years - 80Years
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • 18 to 80 years old
  • Diagnosed with cervical squamous carcinoma confirmed by pathology
  • 2018 FIGO Stage Ib3, II, IIIB, or IIIC1 cervical cancer
  • Planned radical pelvic radiotherapy plus concurrent platinum-based chemotherapy (cisplatin 30-40mg/m2 or carboplatin), starting within first week for at least 5 courses
  • ECOG performance status 0 to 2
  • Life expectancy over 6 months
  • Able to lie down for more than 30 minutes
  • Fully voluntary and able to cooperate, with signed informed consent
  • Complete blood count and metabolic tests within 14 days before enrollment meeting NEUT ≥ 1.5*10^9/L, HGB ≥ 60g/L, platelets ≥ 100x10^9/L, creatinine <1.5 mg/dL, AST and ALT within twice upper limit of normal
  • Completed all baseline assessments before treatment
  • Eligible for regular follow-up
Not Eligible

You will not qualify if you...

  • Previous radiotherapy or chemotherapy
  • Previous radical surgery for cervical cancer
  • History of other malignant tumors
  • Pregnant or breastfeeding
  • Severe uncontrolled cardiovascular, urinary, digestive, respiratory, hematological, or central nervous system diseases

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Peking union medical college hospital

Beijing, China, 100730

Actively Recruiting

Loading map...

Research Team

S

Shuai Sun

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here